Emistat-FT
Generic Name
emistat-ft-8-mg-flash-tablet
Manufacturer
Square Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| emistat ft 8 mg flash tablet | ৳ 11.00 | ৳ 110.00 |
Description
Overview of the medicine
Emistat-FT 8 mg Flash Tablet contains Ondansetron, an antiemetic used to prevent nausea and vomiting caused by chemotherapy, radiation therapy, and surgery.
Uses & Indications
Dosage
Adults
For chemotherapy-induced nausea and vomiting: 8 mg 30 minutes before chemotherapy, followed by 8 mg 8 hours after the first dose, and then 8 mg every 12 hours for 1-2 days. For post-operative nausea and vomiting: 8 mg one hour before anesthesia or 8 mg 1-2 hours before surgery.
Elderly
No dosage adjustment is generally required for elderly patients with normal renal and hepatic function. Caution should be exercised in very elderly patients (over 75 years) due to increased risk of QTc prolongation.
Renal_impairment
No dose adjustment is necessary for patients with renal impairment.
How to Take
Place the tablet on the tongue. It will rapidly dissolve and can be swallowed with saliva. No water is required. Do not push the tablet through the foil packaging.
Mechanism of Action
Ondansetron is a selective 5-HT3 receptor antagonist. It works by blocking serotonin, a natural substance in the body that can cause nausea and vomiting, in both the central nervous system (chemoreceptor trigger zone) and peripherally (vagal nerve terminals in the gut).
Pharmacokinetics
Onset
Within 30 minutes to 2 hours.
Excretion
Approximately 5% of the dose is excreted unchanged in the urine, with the remainder excreted as metabolites via urine and feces.
Half life
Approximately 3-6 hours.
Absorption
Rapidly and completely absorbed from the gastrointestinal tract; oral bioavailability is about 60%. Peak plasma concentrations achieved in 1-2 hours for orally disintegrating tablets.
Metabolism
Extensively metabolized in the liver by hydroxylation, followed by glucuronide or sulfate conjugation, primarily via CYP1A2, CYP2D6, and CYP3A4 enzymes.
Side Effects
Contraindications
- •Hypersensitivity to ondansetron or any component of the formulation.
- •Concomitant use with apomorphine (due to risk of profound hypotension and loss of consciousness).
Drug Interactions
Tramadol
May reduce the analgesic effect of tramadol.
Apomorphine
Concomitant use is contraindicated due to severe hypotension and loss of consciousness.
QTc prolonging drugs
Increased risk of QTc prolongation. Use with caution.
Phenytoin, Carbamazepine, Rifampicin
May decrease ondansetron plasma concentrations, requiring increased ondansetron dosage.
Serotonergic drugs (e.g., SSRIs, SNRIs, Mirtazapine)
Increased risk of serotonin syndrome. Monitor patients for symptoms.
Storage
Store below 30°C in a dry place, away from direct sunlight and moisture. Keep out of reach of children.
Overdose
Symptoms of overdose include transient visual disturbances, severe constipation, hypotension, and vagal episode with transient AV block. Management is supportive and symptomatic, as there is no specific antidote.
Pregnancy & Lactation
Pregnancy Category B. Studies in animals have shown no evidence of harm to the fetus, but there are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if clearly needed. Excreted in human milk; use with caution in nursing mothers.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24-36 months from manufacturing date.
Availability
Pharmacies, Hospitals
Approval Status
Approved
Patent Status
Generic
WHO Essential Medicine
YesAlternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
